Contribution of Leukocyte Adherence Inhibition Test in the Evaluation of Non–IgE-mediated Immunoreactivity against Peanut Proteins in Children and Adults with Atopic Dermatitis

Abstract

Aim: To evaluate the potential of the Leukocyte Adherence Inhibition Test (LAIT) to evaluate immunoreactivity against peanut proteins in patients with a clinical diagnosis of non–IgE-mediated Atopic Dermatitis (AD). Study Design: We retrospectively examined the medical charts of a population of 51 children (0 to 17 years) and 275 adults (18 to 93 years) diagnosed with non–IgE-mediated AD who were investigated with an ex vivo challenge monitored by LAIT against peanut proteins. Place and Duration of Study: Instituto Alergoimuno de Americana – São Paulo – Brazil – between January 2018 and February 2024. Methodology: The percentage of Leukocyte Adherence Inhibition (LAI) promoted by the ex vivo challenges with peanut proteins was distributed in ranges through a cascade distribution chart to outline the variability of the results. Results: In the child cohort, the LAI mean was 48.5%; the median was 52%; SD 27.6%; ranging from 0% to 95%; modes = 0% and 63% (each appeared four times). There was a normal wide range of distribution of LAI results, as outlined by the cascade distribution chart. In the adult cohort, the LAI mean was 43.8%; the median was 46%; SD 28.6%; ranging from 0% to 100%; modes = 0% (appeared 45 times). There was a normal wide range of distribution of LAI results, as outlined by the cascade distribution chart. Conclusion: Our preliminary results support the idea that the LAIT performed with peanut extract may differentiate diverse degrees of ex vivo non–IgE-mediated immunoreactivity against peanut allergens in non–IgE-mediated AD patients, suggesting a potential contribution of LAIT in the stratification of endotypes and the phenotypic classification of non–IgE-mediated AD patients.